Hypokalemia
0 original drugs 0
Novel Drugs
9
Reformulations
0
Active Trials
0
Drug Targets
Hypokalemia has 0 FDA-approved novel treatments. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.
Novel Hypokalemia Drugs by Company (New molecular entities)
No novel drugs found for this indication.
Reformulations (9 drugs) Click to expand
Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.
POKONZA
GENUS
T7 2014
POTASSIUM CHLORIDE 20MEQ IN PLASTIC CONTAINER
Baxter
T5 1989
POTASSIUM CHLORIDE 40MEQ IN PLASTIC CONTAINER
Baxter
T5 1989
POTASSIUM CHLORIDE 10MEQ IN PLASTIC CONTAINER
Baxter
T5 1989
POTASSIUM CHLORIDE 30MEQ IN PLASTIC CONTAINER
Baxter
T5 1989
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
B BRAUN
T5 1989
POTASSIUM CHLORIDE 20MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1988
POTASSIUM CHLORIDE 40MEQ IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
T5 1988
MIDAMOR
PADAGIS US
T1 1981
Generic Drugs (14 ANDA approved) Click to expand
Generic drugs contain the same active ingredient as the brand-name drug and are approved via ANDA (Abbreviated New Drug Application).
AMILORIDE HYDROCHLORIDE
SIGMAPHARM LABS LLC
KLOR-CON M10
UPSHER SMITH LABS
KLOR-CON M15
UPSHER SMITH LABS
KLOR-CON M20
UPSHER SMITH LABS
POTASSIUM CHLORIDE 0.149% IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER
OTSUKA ICU MEDCL
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45%
Baxter
POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9%
Baxter
POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9%
Baxter
POTASSIUM CHLORIDE 10MEQ
Fresenius Kabi
POTASSIUM CHLORIDE 20MEQ
Fresenius Kabi
POTASSIUM CHLORIDE 40MEQ
Fresenius Kabi
POTASSIUM CHLORIDE IN PLASTIC CONTAINER
Fresenius Kabi
TRIAMTERENE
AGNITIO
TRIAMTERENE AND HYDROCHLOROTHIAZIDE
CHARTWELL RX
Drug Categories:
- Novel Drugs: NDA Type 1/2 (new molecular entity) or original BLA
- Reformulations: NDA Type 3/5 (new dosage form of existing molecule)
- Biosimilars: BLA-approved biologics highly similar to reference products
- Generics: ANDA-approved copies of small molecule drugs